TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Research Report 2023

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Research Report 2023

  • Category:Life Sciences
  • Published on : 09 February 2023
  • Pages :89
  • Formats:
  • Report Code:SMR-7556583

Market Analysis and Insights: Global NonAlcoholic Steatohepatitis NASH Drugs Market

The global NonAlcoholic Steatohepatitis NASH Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global NonAlcoholic Steatohepatitis NASH Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global NonAlcoholic Steatohepatitis NASH Drugs market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global NonAlcoholic Steatohepatitis NASH Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global NonAlcoholic Steatohepatitis NASH Drugs market.

Global NonAlcoholic Steatohepatitis NASH Drugs Scope and Market Size

Non-Alcoholic Steatohepatitis (NASH) Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2032.
Segment by Type
  • Vitamin E & Pioglitazone
  • Obeticholic Acid (OCA)
  • Elafibranor
  • Selonsertib & Cenicriviroc
Segment by Application
  • Hospital Pharmacy
  • Online Provider
  • Retail Pharmacy
By Region
  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA
By Company
  • AstraZeneca
  • Conatus Pharmaceuticals
  • Enzo Biochem
  • Galmed Pharmaceuticals
  • Genfit
  • Gilead
  • Horizon Pharma
  • Immuron
  • Intercept Pharmaceuticals
  • Novo Nordisk

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes NonAlcoholic Steatohepatitis NASH Drugs product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of NonAlcoholic Steatohepatitis NASH Drugs, with price, sales, revenue, and global market share of NonAlcoholic Steatohepatitis NASH Drugs from 2019 to 2022.

Chapter 3, the NonAlcoholic Steatohepatitis NASH Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the NonAlcoholic Steatohepatitis NASH Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the NonAlcoholic Steatohepatitis NASH Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of NonAlcoholic Steatohepatitis NASH Drugs.

Chapter 13, 14, and 15, to describe NonAlcoholic Steatohepatitis NASH Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 NonAlcoholic Steatohepatitis NASH Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

TABLE OF CONTENTS

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Vitamin E & Pioglitazone
1.2.3 Obeticholic Acid (OCA)
1.2.4 Elafibranor
1.2.5 Selonsertib & Cenicriviroc
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2018-2032)
2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Region
2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Region (2018-2023)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2023-2032)
2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Dynamics
2.3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Trends
2.3.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2018-2023)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2022
3.5 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2018-2023)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2023-2032)
5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2018-2023)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2032)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2032)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2032)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2032)
9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2032)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.1.5 AstraZeneca Recent Development
11.2 Conatus Pharmaceuticals
11.2.1 Conatus Pharmaceuticals Company Detail
11.2.2 Conatus Pharmaceuticals Business Overview
11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.2.5 Conatus Pharmaceuticals Recent Development
11.3 Enzo Biochem
11.3.1 Enzo Biochem Company Detail
11.3.2 Enzo Biochem Business Overview
11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.3.5 Enzo Biochem Recent Development
11.4 Galmed Pharmaceuticals
11.4.1 Galmed Pharmaceuticals Company Detail
11.4.2 Galmed Pharmaceuticals Business Overview
11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.4.5 Galmed Pharmaceuticals Recent Development
11.5 Genfit
11.5.1 Genfit Company Detail
11.5.2 Genfit Business Overview
11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.5.5 Genfit Recent Development
11.6 Gilead
11.6.1 Gilead Company Detail
11.6.2 Gilead Business Overview
11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.6.5 Gilead Recent Development
11.7 Horizon Pharma
11.7.1 Horizon Pharma Company Detail
11.7.2 Horizon Pharma Business Overview
11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.7.5 Horizon Pharma Recent Development
11.8 Immuron
11.8.1 Immuron Company Detail
11.8.2 Immuron Business Overview
11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.8.5 Immuron Recent Development
11.9 Intercept Pharmaceuticals
11.9.1 Intercept Pharmaceuticals Company Detail
11.9.2 Intercept Pharmaceuticals Business Overview
11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.9.5 Intercept Pharmaceuticals Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Detail
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2032
Table 2. Key Players of Vitamin E & Pioglitazone
Table 3. Key Players of Obeticholic Acid (OCA)
Table 4. Key Players of Elafibranor
Table 5. Key Players of Selonsertib & Cenicriviroc
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2032
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2032
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2018-2023)
Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2023-2032) & (US$ Million)
Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2023-2032)
Table 12. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
Table 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
Table 14. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
Table 15. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
Table 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2018-2023)
Table 18. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2022)
Table 19. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
Table 23. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2018-2023)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2023-2032) & (US$ Million)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2023-2032)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2018-2023)
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2023-2032) & (US$ Million)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2023-2032)
Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2032) & (US$ Million)
Table 35. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2032) & (US$ Million)
Table 37. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2023-2032) & (US$ Million)
Table 39. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 40. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2032) & (US$ Million)
Table 41. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 42. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2032) & (US$ Million)
Table 43. AstraZeneca Company Detail
Table 44. AstraZeneca Business Overview
Table 45. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 46. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 47. AstraZeneca Recent Development
Table 48. Conatus Pharmaceuticals Company Detail
Table 49. Conatus Pharmaceuticals Business Overview
Table 50. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 51. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 52. Conatus Pharmaceuticals Recent Development
Table 53. Enzo Biochem Company Detail
Table 54. Enzo Biochem Business Overview
Table 55. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 56. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 57. Enzo Biochem Recent Development
Table 58. Galmed Pharmaceuticals Company Detail
Table 59. Galmed Pharmaceuticals Business Overview
Table 60. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 61. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 62. Galmed Pharmaceuticals Recent Development
Table 63. Genfit Company Detail
Table 64. Genfit Business Overview
Table 65. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 66. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 67. Genfit Recent Development
Table 68. Gilead Company Detail
Table 69. Gilead Business Overview
Table 70. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 71. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 72. Gilead Recent Development
Table 73. Horizon Pharma Company Detail
Table 74. Horizon Pharma Business Overview
Table 75. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 76. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 77. Horizon Pharma Recent Development
Table 78. Immuron Company Detail
Table 79. Immuron Business Overview
Table 80. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 81. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 82. Immuron Recent Development
Table 83. Intercept Pharmaceuticals Company Detail
Table 84. Intercept Pharmaceuticals Business Overview
Table 85. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 86. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 87. Intercept Pharmaceuticals Recent Development
Table 88. Novo Nordisk Company Detail
Table 89. Novo Nordisk Business Overview
Table 90. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 91. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 92. Novo Nordisk Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2022 VS 2032
Figure 2. Vitamin E & Pioglitazone Features
Figure 3. Obeticholic Acid (OCA) Features
Figure 4. Elafibranor Features
Figure 5. Selonsertib & Cenicriviroc Features
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application in 2022 & 2032
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Online Provider Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), Year-over-Year: 2018-2032
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2032
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region: 2022 VS 2032
Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2022
Figure 15. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2022
Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 18. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2032)
Figure 19. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 20. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 21. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 22. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2032)
Figure 23. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 24. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 25. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 26. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 27. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 28. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 29. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 30. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2018-2032)
Figure 31. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 32. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 33. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 34. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 35. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 36. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 37. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 38. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2032)
Figure 39. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 40. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 41. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 42. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2032)
Figure 43. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 44. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 45. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 46. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 47. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 48. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 49. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 50. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 51. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 52. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 53. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 54. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed

Offer REPORT BUYING OPTIONS

USD GBP EURO YEN Single User Price
USD GBP EURO YEN Multi User Price
USD GBP EURO YEN Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount